An in silico study of the molecular basis of B-RAF activation and conformational stability

BMC Structural Biology

Volumn 9, Issue , 2009, Pages

  Fratev, Filip F ^a   Jónsdóttir, Svava Ó ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; B RAF KINASE; GLUTAMINE; LYSINE; MUTANT PROTEIN;

ARTICLE; COMPUTER MODEL; ELECTRIC ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME STABILITY; GENE MUTATION; HYDROGEN BOND; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; AMINO ACID SUBSTITUTION; CHEMISTRY; COMPUTER PROGRAM; COMPUTER SIMULATION; MUTATION; PROTEIN DATABASE; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SUBSTITUTION; COMPUTER SIMULATION; DATABASES, PROTEIN; ENZYME ACTIVATION; MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS B-RAF; SOFTWARE;

EID: 69249194669     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-9-47     Document Type: Article

References (25)

1. RAS oncogenes: the first 30 years. M Malumbres M Barbacid, Nat Rev Cancer 2003 3 459 465 10.1038/nrc1097 12778136 (Pubitemid 37328850)
2. Mutations of the BRAF gene in human cancer. H Davies GR Bignell C Cox P Stephens S Edkins S Clegg J Teague H Woffendin MJ Garnett W Bottomley N Davis E Dicks R Ewing Y Floyd K Gray S Hall R Hawes J Hughes V Kosmidou A Menzies C Mould A Parker C Stevens S Watt S Hooper R Wilson H Jayatilake BA Gusterson C Cooper J Shipley D Hargrave K Pritchard-Jones N Maitland G Chenevix-Trench GJ Riggins DD Bigner G Palmieri A Cossu A Flanagan A Nicholson JW Ho SY Leung ST Yuen BL Weber HF Seigler TL Darrow H Paterson R Marais CJ Marshall R Wooster MR Stratton PA Futreal, Nature 2002 417 949 954 10.1038/nature00766 12068308 (Pubitemid 34716871)
3. BRAFE600 in benign and malignant human tumours. C Michaloglou LCW Vredeveld WJ Mooi DS Peeper, Oncogene 2008 27 877 895 10.1038/sj.onc.1210704 17724477 (Pubitemid 351225383)
4. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. PT Wan MJ Garnett SM Roe S Lee D Niculescu-Duvaz VM Good CM Jones CJ Marshall CJ Springer D Barford R Marais, Cell 2004 116 855 867 10.1016/S0092-8674(04)00215-6 15035987 (Pubitemid 38410730)
5. Activation of B-RAF kinase requires phosphorylation of the conserved residues Thr598 and Ser601. BH Zhang KL Guan, EMBO J 2000 19 5429 5439 11032810 10.1093/emboj/19.20.5429
6. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. OM Grbovic AD Basso A Sawai Q Ye P Friedlander D Solit N Rosen, Proc Natl Acad Sci USA 2006 103 57 62 16371460 10.1073/pnas.0609973103 (Pubitemid 43076104)
7. The Eleventh Data Lecture. The structural basis for substrate recognition and control by protein kinases. LN Johnson ED Lowe ME Noble DJ Owen, FEBS Lett 1998 430 1 11 10.1016/S0014-5793(98)00606-1 9678585 (Pubitemid 28307022)
8. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. NJ Dibb SM Dilworth CD Mol, Nat Rev Cancer 2004 4 718 727 10.1038/nrc1434 15343278 (Pubitemid 39215070)
9. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. J Tsai JT Lee W Wang J Zhang H Cho S Mamo R Bremer S Gillette J Kong NK Haass K Sproesser L Li KS Smalley D Fong YL Zhu A Marimuthu H Nguyen B Lam J Liu I Cheung J Rice Y Suzuki C Luu C Settachatgul R Shellooe J Cantwell SH Kim KY Schlessinger KBL Zhang B West G Powell C Habets PN Zhang J Ibrahim P Hirth DR Artis M Herlyn G Bollag, Proc Natl Acad Sci USA 2008 105 3041 3046 18287029 10.1073/pnas.0711741105 (Pubitemid 351723664)
10. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. S Moretti A Macchiarulo V De Falco N Avenia F Barbi C Carta A Cavaliere RM Melillo L Passeri F Santeusanio M Tartaglia M Santoro E Puxeddu, Oncogene 2006 25 4235 4240 10.1038/sj.onc.1209448 16501605 (Pubitemid 44079457)
11. V600Eligand inhibition, selectivity and conformational stability: An in silico study. F Fratev S Jnsdttir E Mihaylova I Pajeva, Mol Pharm. 2009 6 1 144 157 10.1021/mp8001107 19248232
12. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. AJ King DR Patrick RS Batorsky ML Ho HT Do SY Zhang R Kumar DW Rusnak AK Takle DM Wilson E Hugger L Wang F Karreth JC Lougheed J Lee D Chau TJ Stout EW May CM Rominger MD Schaber L Luo AS Lakdawala JL Adams RG Contractor KS Smalley M Herlyn MM Morrissey DA Tuveson PS Huang, Cancer Res 2006 66 11100 11105 10.1158/0008-5472.CAN-06-2554 17145850 (Pubitemid 46009933)
13. The Protein Data Bank. HM Berman J Westbrook Z Feng G Gilliland TN Bhat H Weissig IN Shindyalov PE Bourne, Nucleic Acids Res 2000 28 235 242 10592235 10.1093/nar/28.1.235
14. Comparative protein structure modeling of genes and genomes. MA Marti-Renom A Stuart A Fiser R Sánchez F Melo A ali, Annu Rev Biophys Biomol Struct 2000 29 291 325 10.1146/annurev.biophys.29.1.291 10940251 (Pubitemid 30599596)
15. DA Case TA Darden TE Cheatham III CL Simmerling J Wang RE Duke R Luo KM Merz DA Pearlman M Crowley RC Walker W Zhang B Wang S Hayik A Roitberg G Seabra KF Wong F Paesani X Wu S Brozell V Tsui H Gohlke L Yang C Tan J Mongan V Hornak G Cui P Beroza DH Mathews C Schafmeister WS Ross PA Kollman, AMBER 9 (University of California, San Francisco) 2006
16. Scalable molecular dynamics with NAMD. CP James R Braun W Wang J Gumbart E Tajkhorshid E Villa C Chipot RD Skeel L Kale K Schulten, J Comput Chem 2005 26 1781 1802 16222654 10.1002/jcc.20289 (Pubitemid 43078511)
17. The missing terms in effective pair potentials. HJ Berendsen J Grigera T Straatsma, J Phys Chem 1987 91 6269 6271 10.1021/j100308a038
18. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. WD Cornell P Cieplak CI Bayey I Gould KM Merz DM Ferguson D Spellmeyr T Fox JW Caldmell P Kollman, J Am Chem Soc 1995 117 5179 5197 10.1021/ja00124a002
19. Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. JP Ryckaert G Ciccotti HJC Berendsen, J Comput Phys 1977 23 327 341 10.1016/0021-9991(77)90098-5
20. Particle mesh Ewald: an N.log (N) method for Ewald sums in large systems. T Darden D York L Pederson, J Chem Phys 1993 98 10089 10092 10.1063/1.464397
21. VEGA: a versatile program to convert, handle and visualize molecular structure on Windows-based PCs. A Pedretti L Villa G Vistoli, J Mol Graph 2002 21 47 49 10.1016/S1093-3263(02)00123-7 (Pubitemid 34628493)
22. VMD Visual Molecular Dynamics. W Humphrey A Dalke K Schulten, J Mol Graph 1996 14 33 38 10.1016/0263-7855(96)00018-5 8744570 (Pubitemid 26152973)
23. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. TS Lee SJ Potts H Kantarjian J Cortes F Giles M Albitar, Cancer 2008 112 1744 1753 10.1002/cncr.23355 18338744
24. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure andclassification. SK Hanks T Hunter, FASEB J 1995 9 576 596 7768349
25. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. JJ Liao, J Med Chem 2007 50 409 424 10.1021/jm0608107 17266192 (Pubitemid 46239775)